跳至主要内容
临床试验/NCT01264159
NCT01264159终止不适用

Preemptive Lung Impedance-guided Therapy of Evolving Acute Heart Failure in Acute Myocardial Infarction Patients

Hillel Yaffe Medical Center2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2011年1月1日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
70
试验地点
2
主要终点
Prevention of acute heart failure development in acute MI patients

研究概览

简要总结

It is well known that 20-25% of patients hospitalized for acute myocardial infarction will develop acute heart failure during their hospitalization. Currently, the investigators have no reliable parameter for prediction of evolving acute heart failure in such a group of patients. As a result, the investigators have no way of preventing acute heart failure. Treatment of these patients only begins after appearance of clinical signs of acute heart failure. Lung impedance monitoring may be a good non-invasive parameter for prediction of evolving acute heart failure. This study will attempt to address whether preemptive lung impedence-guided therapy may prevent the development of overt acute heart failure and improve their clinical outcome.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients hospitalized in the ICCU for acute myocardial infarction and developing acute heart failure during their hospitalization

排除标准

  • Patients with acute myocardial infarction with clinical and radiological signs of acute heart failure at admission

结局指标

主要结局

Prevention of acute heart failure development in acute MI patients

时间窗: Three years

次要结局

  • Improvement of clinical outcome in patients with lung impedence-guided treatments(Three years)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

Preemptive Lung Impedance-guided Therapy of Evolving... | 临床试验